These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 2123366

  • 1. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M, Nardi AE, Figueira IL, Stabl M.
    Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
    Lecrubier Y, Guelfi JD.
    Acta Psychiatr Scand Suppl; 1990; 360():18-23. PubMed ID: 2248063
    [Abstract] [Full Text] [Related]

  • 3. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [Abstract] [Full Text] [Related]

  • 4. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R, Hetzel W, Stabl M, Schmid-Burgk W.
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [Abstract] [Full Text] [Related]

  • 5. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J, Kneer J, Fotteler B, Groen H, Peeters PA, Jonkman JH.
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview.
    Amrein R, Stabl M, Henauer S, Affolter E, Jonkanski I.
    Can J Psychiatry; 1997 Dec; 42(10):1043-50. PubMed ID: 9469236
    [Abstract] [Full Text] [Related]

  • 7. Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.
    Ucha Udabe R, Márquez CA, Traballi CA, Portes N.
    Acta Psychiatr Scand Suppl; 1990 Dec; 360():54-6. PubMed ID: 2123367
    [Abstract] [Full Text] [Related]

  • 8. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.
    Versiani M, Amrein R, Stabl M.
    Int Clin Psychopharmacol; 1997 Jul; 12(4):183-93. PubMed ID: 9347378
    [Abstract] [Full Text] [Related]

  • 9. Moclobemide, imipramine and placebo in the treatment of major depression.
    Versiani M, Nardi AE, Mundim FD, Alves A, Schmid-Burgk W.
    Acta Psychiatr Scand Suppl; 1990 Jul; 360():57-8. PubMed ID: 2248073
    [Abstract] [Full Text] [Related]

  • 10. Moclobemide: therapeutic use and clinical studies.
    Bonnet U.
    CNS Drug Rev; 2003 Jul; 9(1):97-140. PubMed ID: 12595913
    [Abstract] [Full Text] [Related]

  • 11. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
    Stabl M, Biziére K, Schmid-Burgk W, Amrein R.
    J Neural Transm Suppl; 1989 Jul; 28():77-89. PubMed ID: 2677244
    [Abstract] [Full Text] [Related]

  • 12. Moclobemide--placebo-controlled trials.
    Silverstone T.
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):133-6. PubMed ID: 8468433
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K, Berger M.
    Acta Psychiatr Scand Suppl; 1990 Jan; 360():59-60. PubMed ID: 2248074
    [Abstract] [Full Text] [Related]

  • 14. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR, Burrows GD.
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [Abstract] [Full Text] [Related]

  • 15. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW, Maguire KP, Davies BM.
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [Abstract] [Full Text] [Related]

  • 16. Moclobemide. An update of its pharmacological properties and therapeutic use.
    Fulton B, Benfield P.
    Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
    [Abstract] [Full Text] [Related]

  • 17. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP, Tsoi WF.
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [Abstract] [Full Text] [Related]

  • 18. [Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes].
    Barrelet L, Blajev B, Bolzani L, de Saussure C, Kasas A, Van H, Gachoud JP.
    Schweiz Rundsch Med Prax; 1991 May 07; 80(19):524-8. PubMed ID: 1904620
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M, Guelfi JD.
    Can J Psychiatry; 1992 Sep 07; 37 Suppl 1():18-24. PubMed ID: 1394027
    [Abstract] [Full Text] [Related]

  • 20. The role of moclobemide in endogenous depression: a survey of recent data.
    Woggon B.
    Int Clin Psychopharmacol; 1993 Jan 07; 7(3-4):137-9. PubMed ID: 8468434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.